ANXA3 and laryngotracheoesophageal cleft: Except for TMEM176A, only three genes (ANXA3, ARG1 and HP) showed consistently > 10% change in risk in all three comparisons (all LC cases vs. FalsePos, NSCLC cases vs. FalsePos and late-stage LC cases vs. FalsePos), though these were statistically significant only for all LC cases versus FalsePos without smoking adjustment (Supplementary Table S5).